title: Glucagon-like peptide 1 and appetite.
abstract: Glucagon-like peptide 1 (GLP-1) and GLP-1 analogs have received much recent attention due to the success of GLP-1 mimetics in treating type II diabetes mellitus (T2DM), but these compounds may also have the potential to treat obesity. The satiety effect of GLP-1 may involve both within-meal enteroenteric reflexes, and across-meal central signaling mechanisms, that mediate changes in appetite and promote satiety. Here, we review data supporting the role of both peripheral and central GLP-1 signaling in the control of gastrointestinal motility and food intake. Understanding the mechanisms underlying the appetite-suppressive effects of GLP-1 may help in developing targeted treatments for obesity.
authors: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. mdailey5@jhmi.edi
authors: Megan J
authors: MJ
authors: Dailey
authors: Timothy H
authors: TH
authors: Moran
mesh_terms: D001066:Appetite / Q000502:physiology*; D004435:Eating / Q000502:physiology; D005769:Gastrointestinal Motility / Q000502:physiology; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism*; D006801:Humans
chemical_list: D052216:Glucagon-Like Peptide 1